2 Unstoppable Stocks That Could Make You Richer in 2023 and Beyond

01:45pm, Friday, 02'nd Dec 2022 The Motley Fool
It would take a lot to throw these leaders off their game.

2 Healthcare Stocks That Could Help Your Portfolio

01:07pm, Friday, 02'nd Dec 2022 The Motley Fool
These two companies have each delivered market-topping total returns over the last 10 years.
Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.
Major Chinese cities are further easing COVID restrictions, though police continue to patrol streets to avert protests.
US stocks are on track for a nervous start on Friday as traders look ahead to the November non-farm payrolls report for trading cues. With the Federal Reserve signaling its intention to potentially pi
It would take a lot to throw these leaders off their game.
The FDA said bebtelovimab is no longer authorized for use because it is not expected to neutralize the omicron BQ.1 and BQ.1.1 subvariants.

Why Is Lilly (LLY) Up 4.5% Since Last Earnings Report?

04:31pm, Thursday, 01'st Dec 2022 Zacks Investment Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Lilly's (LLY) Donanemab Betters Biogen's Alzheimer's Drug

01:09pm, Thursday, 01'st Dec 2022 Zacks Investment Research
Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after s
Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after s
Amgen stock could get a fresh boost Thursday after the company unveiled promising results for its obesity treatment. The post Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Nov
Eli Lilly & Co. LLY, +1.96% said Wednesday night that its experimental Alzheimer's treatment did a better job at clearing amyloid plaque than Eisai and Biogen's Aduhelm in a Phase 3 clinical trial. Am
Eisai plans to share additional data about the Alzheimer’s disease treatment it's developing with Biogen this week.
Amid rising concerns about the state of the global economy, rising inflation, central bank interest rate hikes and increased Covid-19 restrictions in China, marked indexes were mixed on Wednesday morn
Eli Lilly and Company (NYSE:LLY ) 5th Annual Evercore ISI HealthCONx Conference 2022 Conference Call November 30, 2022 12:10 PM ET Company Participants Jacob Van Naarden - Executive Vice President and
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE